CD19 and neoplasm: Pre-clinical trials of NKTR-255 have demonstrated enhanced anti-tumor activity and survival as a monotherapy, as well as in combination with monoclonal antibodies (mAbs) and with CD19-CAR T cell therapies [40,75].